Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | -0.00 | -0.00 | 6.88 |
| FCF Yield | 7.73% | -0.67% | -1.60% | -3.37% |
| EV / EBITDA | 13.64 | 14.54 | -29.13 | -78.52 |
| Quality | ||||
| ROIC | 739.17% | 4.12% | -5.56% | -5.96% |
| Gross Margin | 61.81% | -105.27% | 54.69% | 52.32% |
| Cash Conversion Ratio | -9.14 | -0.00 | -0.46 | 50.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.45% | 29.18% | 45.46% | 42.59% |
| Free Cash Flow Growth | 1,207.57% | 66.58% | 68.58% | 35.60% |
| Safety | ||||
| Net Debt / EBITDA | 1.22 | 0.21 | -0.41 | 20.53 |
| Interest Coverage | 19.61 | 8.29 | -5.21 | -11.43 |
| Efficiency | ||||
| Inventory Turnover | 5.11 | 2.19 | 5.00 | 4.01 |
| Cash Conversion Cycle | 17.06 | 324.31 | 18.01 | 65.73 |